| This week's sponsor is RAPS. | |  | |
Featured Story | | | Tuesday, July 11, 2017 After a series of talks with the FDA, Amicus, the biotech at the center of president Donald Trump’s campaign to speed up drug development, can now submit its rare disease drug for review. |
|
|
Top Stories Monday, June 12, 2017 Some of the executive pay rankings are predictable, like Johnson & Johnson's CEO, regardless who's in the job. What's not guaranteed is that the chairman of a generics maker in hot water with the U.S. government and American parents—Mylan's Robert Coury—would step off the company’s employee roster and into the nonexecutive chairman’s job and reap a $97 million package with the move. Tuesday, July 11, 2017 It’s been a good week for Neon: After posting positive cancer vaccine data a few days ago, it has signed a new R&D pact with gene-editing biotech CRISPR Therapeutics. Tuesday, July 11, 2017 Arena Pharmaceuticals has posted positive data from a phase 2 trial of its pulmonary arterial hypertension candidate ralinepag. The trial linked ralinepag to improvements in pulmonary vascular resistance, sending Arena’s stock up 41% and putting it on a path that could lead to a showdown with Johnson & Johnson. Tuesday, July 11, 2017 Evelo Biosciences has raised $50 million to take its monoclonal microbials into the clinic. The series B round moves the total raised by the preclinical-stage Flagship VentureLabs graduate up toward the $100 million mark, equipping it to push cancer and immuno-inflammatory drugs into phase 1. Monday, July 10, 2017 In the second part of our video interview series, we delve into the R&D strategy for Allergan, a company that last year was on the cusp of becoming subsumed in a major merger with Pfizer. Monday, July 10, 2017 As part of our new video interview series, we sat down with Rowan Chapman, head of J&J Innovation California, to get her thoughts on what the big pharma company wants to see from its potential life science partners. Tuesday, July 11, 2017 Private equity firm EQT is acquiring in silico drug development service provider Certara from Arsenal Capital Partners, a deal that values the CRO at $850 million, Arsenal announced on Tuesday. | | | Daiichi Sankyo, Max Planck Innovation and the Lead Discovery Center have signed a new pact giving Daiichi the option to nab exclusive rights to a new cancer compound from the LDC. Statement Gene therapy biotech uniQure has posted new data which it says shows that the presence of pre-existing anti-AAV5 neutralizing antibodies does not predict the potential efficacy of AAV5-mediated gene transfer in patients with hemophilia B. Release ArQule says its first patient has been dosed in an early test with its BTK inhibitor, ARQ 531, in patients with B-cell malignancies who can't use other meds, with plans to enroll up to 120 patients. Statement | |
|
Resources Sponsored By: Veeva Learn why 99% of respondents report the need to unify their clinical applications, including CTMS, EDC, eTMF, and study start-up. Sponsored By: HealthCore Gain critical insights into how to design and implement pragmatic trials and generate relevant, high-level real-world evidence. Learn when to conduct PTs, design considerations, ethical regulatory issues — and more. Sponsored By: Envigo Discover the factors that contribute to differential radiation sensitivity between the Rag2 and SCID models. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Sponsored By: Veeva Join this global webinar to learn a new approach for demonstrating medical affairs' impact with better metrics - beyond reach and frequency, enabling launch success and better engagement with strategic KOL insights, and increasing your organization's share of voice in the healthcare landscape. Sponsored By: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Sponsored By: DocuSign The patients who rely on your scientific leadership are expecting more. Sponsored By: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. |
|
